Abstract
Inflammatory bowel disease (IBD) is associated with many extra-intestinal effects, including cutaneous manifestations (CMs). Affecting up to 20% of IBD patients, CMs may be direct extensions of, or more indirectly associated with, IBD. Both the CM and underlying IBD may require treatment; simple analgesics, corticosteroids, calcineurin inhibitors, immune modulators, anti-tumour necrosis factor ⍺ agents and other biologicals, often with antibiotics, are key therapies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pagani K, Lukac D, Bhukhan A, et al. Cutaneous manifestations of inflammatory bowel disease: a basic overview. Am J Clin Dermatol. 2022;23(4):481–97.
Okobi OE, Udoete IO, Fasehun OO, et al. A review of four practice guidelines of inflammatory bowel disease. Cureus. 2021;13(8): e16859.
Jansen FM, Vavricka SR, Broeder AA, et al. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. United Eur Gastroenterol J. 2020;8(9):1031–44.
van Wijk F, Cheroutre H. Mucosal T cells in gut homeostasis and inflammation. Expert Rev Clin Immunol. 2010;6(4):559–66.
Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:1–13.
Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017;53(3):413–27.
Cleynen I, Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.
Campbell HE, Escudier MP, Patel P, et al. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther. 2011;34(7):687–701.
Espinoza I, Navarrete J, Benedetto J, et al. Orofacial granulomatosis and diet therapy: a review of the literature and two clinical cases. An Bras Dermatol. 2018;93(1):80–5.
Nesbitt E, Clements S, Driscoll M. A concise clinician’s guide to therapy for hidradenitis suppurativa. Int J Womens Dermatol. 2020;6(2):80–4.
Iwata H, Vorobyev A, Koga H, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018. https://doi.org/10.1186/s13023-018-0896-1.
Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181–4.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
C. Fenton, a contracted employee for Adis International Ltd/Springer Nature, and A. Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fenton, C., Lee, A. Common skin conditions in inflammatory bowel disease are manageable. Drugs Ther Perspect 39, 191–194 (2023). https://doi.org/10.1007/s40267-023-00998-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-023-00998-y